This trial is testing the side effects of directly injecting drugs into tumors and using FDG-PET to see which drugs are most effective in treating non-Hodgkin lymphoma, Hodgkin lymphoma, or breast cancer.
1 Primary · 6 Secondary · Reporting Duration: Up to 3 months
39 Total Participants · 1 Treatment Group
Primary Treatment: Gemcitabine Hydrochloride · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: